Searchable abstracts of presentations at key conferences in endocrinology

ea0049s9.1 | Novel type 2 diabetes treatment: Beyond glycaemic control | ECE2017

Experimental models

Holst Jens

One of the most surprising and inspiring experimental models for type 2 diabetes therapy is gastric bypass surgery. Recent 5-year results have demonstrated massive improvements in glycaemic control and body weight, lipids and quality of life after surgery compared to intensive medical therapy (the Stampede trial). Therefore, it is imperative to identify the responsible factors with a view to utilize this knowledge for future therapy without surgery. Substantial evidence sugges...

ea0050oc2.6 | Clinical Highlights | SFEBES2017

Reduced early GLP-1 response in gestational diabetes is associated with hyperinsulinaemia and insulin resistance: a prospective case-control study

Sukumar Nithya , Bagias Christos , Goljan Ilona , Gharanei Seley , Tan Bee , Juls Holst Jens , Sa Ponnusamy

Background: Glucagon-like peptide-1 (GLP-1) concentrations are reduced by 20–50% in type 2 diabetes but studies in women with gestational diabetes mellitus (GDM) are inconclusive. Our aim was to study the GLP-1 profile during a glucose tolerance test (GTT) at GDM diagnosis and its relationship with insulin levels.Methods: A prospective study of selectively screened women was conducted. Plasma GLP-1, insulin and glucose were measured at 30-minute int...

ea0050oc2.6 | Clinical Highlights | SFEBES2017

Reduced early GLP-1 response in gestational diabetes is associated with hyperinsulinaemia and insulin resistance: a prospective case-control study

Sukumar Nithya , Bagias Christos , Goljan Ilona , Gharanei Seley , Tan Bee , Juls Holst Jens , Sa Ponnusamy

Background: Glucagon-like peptide-1 (GLP-1) concentrations are reduced by 20–50% in type 2 diabetes but studies in women with gestational diabetes mellitus (GDM) are inconclusive. Our aim was to study the GLP-1 profile during a glucose tolerance test (GTT) at GDM diagnosis and its relationship with insulin levels.Methods: A prospective study of selectively screened women was conducted. Plasma GLP-1, insulin and glucose were measured at 30-minute int...

ea0032oc6.3 | Diabetes & Obesity | ECE2013

Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin–angiotensin–aldosterone system in healthy men

Skov Jeppe , Dejgaard Anders , Frokiaer Jorgen , Holst Jens Juul , Jonassen Thomas , Rittig Soren , Christiansen Jens Sandahl

Glucagon-like peptide-1 (GLP-1) is an incretine hormone with multiple actions besides control of glucose homeostasis. GLP-1 is known to cause natriuresis in humans but the effects on basic renal physiology are still partly unknown.This study therefore aimed to demonstrate the effects of GLP-1 on kidney hemodynamics, electrolyte handling, and the renin–angiotensin–aldosterone system in healthy men.Twelve healthy young male...

ea0038p152 | Neoplasia, cancer and late effects | SFEBES2015

Phenotypic heterogeneity associated with proglucagon-expressing tumours is due to differential processing and secretion of proglucagon-derived peptides

Challis Ben , Albrechtsen Nicolai , Bansiya Vishakha , Burling Keith , Barker Peter , Hartmann Bolette , Gribble Fiona , O'Rahilly Stephen , Holst Jens , Simpson Helen

Context: Pancreatic neuroendocrine tumours (NETs) overexpressing glucagon are associated with phenotypic heterogeneity. Objective: To correlate clinical phenotype with detailed analysis of plasma levels of proglucagon-derived peptides (PGDPs) in subjects with proglucagon-expressing tumours using specific immunoassays and gel filtration profiles to elaborate molecular heterogeneity of PGDPs, before and after somatostatin analogues.Case 1: A 57 year old wo...

ea0038p208 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Bile acids stimulate GLP-1 release predominantly by accessing basolateral GPBAR1 (TGR5)

Brighton Cheryl A , Rievaj Juraj , Kuhre Rune E , Glass Leslie L , Holst Jens J , Gribble Fiona M , Reimann Frank

Background: Glucagon-like peptide 1 (GLP-1) is an incretin hormone released from enteroendocrine L-cells in the gut. GLP-1 analogues and dipeptidyl-peptidase-4 inhibitors are currently used to treat type-2 diabetes. A greater understanding of the mechanisms underlying the release of GLP-1 may facilitate the development of therapeutics to stimulate the release of endogenous GLP-1. Bile acids have been shown to induce GLP-1 release via the G protein-coupled bile acid receptor 1 ...

ea0073aep507 | Pituitary and Neuroendocrinology | ECE2021

Treatment regimens affecting glucose metabolism and gastrointestinal hormones in acromegaly: A descriptive study

Nanna Jørgensen , Erichsen Trine , Klose Marianne , Joergensen Morten , Idorn Thomas , Feldt-Rasmussen Bo , Holst Jens J. , Feldt-Rasmussen Ulla

ContextActive acromegaly is associated with impaired glucose metabolism, which improves upon treatment. Treatment options include surgery, medical therapy with somatostatin analogues (SSA) and Pegvisomant (PEG) and in few cases irradiation.ObjectiveTo describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (GLP1), and glucose-depen...

ea0099oc4.4 | Oral Communications 4: Diabetes, Obesity, Metabolism and Nutrition | Part I | ECE2024

Sphinganine increases GLP-1 secretion and causes weight loss in mice

Smits Mark , Drzazga Anna , Galsgaard Katrine , Lackman Jarkko , Gerdes Victor , van de Laar Arnold , Bruin Sjoerd , Rosenkilde Mette , Holst Jens J.

Recent years have demonstrated increasing focus on augmenting secretion of glucagon-like peptide (GLP)-1 from intestinal L cells, to improve the treatment and/or prevention of obesity and type 2 diabetes. However, finding strong stimuli and identifying novel compounds has proven difficult. To discover new GLP-1 secretagogues, we gave 49 individuals (76% female, BMI 28.3±4.8 kg/m2) a high-fat liquid mixed meal (250 mL Nutridrink, Nutricia®). Plasma samples,...

ea0067o24 | Oral Presentations | EYES2019

Proglucagon peptide family responses after RYGB surgery in obese patients with type 2 diabetes

Alexiadou Kleopatra , Cuenco Joyceline , Howard James W , Fleuret Matthieu , Behary Preeshila , Tharakan George , Albrechtsen Nicolai J Wewer , Holst Jens Juul , Pembroke Jason , Wheller Robert , Ahmed Ahmed R , Bloom Steve R , Tan Tricia M

Objective: Bariatric surgery is currently the most effective treatment for weight loss and diabetes remission. There are conflicting reports in the literature regarding the glucagon levels after RYGB surgery, likely due to cross-reactivity with oxyntomodulin and glicentin. The aim of this study was to characterize the proglucagon peptide family responses post-RYGB surgery in obese patients with type 2 diabetes using validated assays.Method: Nineteen obes...